Ann: Kazia paxalisib Phase II interim data, page-12

BB- I think I was wrong about it being Pax on it's own. "This phase 2 study comprises an open-label, multicenter, dose-escalation and expansion study to assess the safety, tolerability, RP2D, PK and clinical activity of GDC 0084 in patients with newly-diagnosed GBM with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and initial chemoradiation with TMZ."

So patients have been treated with TMZ. Still, results in the unmethylated MGMT-promoter group are superior to TMZ in the methylated MGMT-promoter group, and that's the only group that TMZ works on. Pax will treat 65% of patients better than TMZ treats 35% of the patients.

We've yet to see Pax vs. methylated MGMT-promoter group, unless I'm missing something. My shoddy memory and research leaves a great opportunity for others!I